Journal Article
. 2009 Jul;27(24).
doi: 10.1200/JCO.2009.22.3701.

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges

Sumithra J Mandrekar 1 Daniel J Sargent  
Affiliations
  • PMID: 19597023
  •     41 References
  •     116 citations

Abstract

Purpose: Biomarkers can add substantial value to current medical practice by providing an integrated approach to prediction using the genetic makeup of the tumor and the genotype of the patient to guide patient-specific treatment selection. We discuss and evaluate various clinical trial designs for the validation of biomarker-guided therapy.

Methods: Designs for predictive marker validation are broadly classified as retrospective (ie, using data from previously well-conducted randomized controlled trials [RCTs]) versus prospective (enrichment, unselected, hybrid, or adaptive analysis). We discuss the salient features of each design in the context of real trials.

Results: Well-designed retrospective analysis from well-conducted prospective RCTs can bring forward effective treatments to marker-defined subgroups of patients in a timely manner (eg, KRAS and colorectal cancer). Enrichment designs are appropriate when preliminary evidence suggest that patients with or without that marker profile do not benefit from the treatments in question; however, this may sometimes leave questions unanswered (eg, trastuzumab and breast cancer). An unselected design is optimal where preliminary evidence regarding treatment benefit and assay reproducibility is uncertain (eg, epidermal growth factor receptor and lung cancer). Hybrid designs are appropriate when preliminary evidence demonstrate the efficacy of certain treatments for a marker-defined subgroup, making it unethical to randomly assign patients with that marker status to other treatments (eg, multigene assay and breast cancer). Adaptive analysis designs allow for prespecified marker-defined subgroup analyses of data from an RCT.

Conclusion: The implementation of these design strategies will lead to a more rapid clinical validation of biomarker-guided therapy.

A method for testing a prespecified subgroup in clinical trials.
Yang Song, George Y H Chi.
Stat Med, 2007 Feb 03; 26(19). PMID: 17266164
Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer.
Maureen Cronin, Chithra Sangli, +7 authors, Drew Watson.
Clin Chem, 2007 Apr 28; 53(6). PMID: 17463177
Highly Cited.
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Pasi A Jänne, Bruce E Johnson.
Clin Cancer Res, 2006 Jul 22; 12(14 Pt 2). PMID: 16857820
Review.
Cancer diagnostics: decision criteria for marker utilization in the clinic.
Sheila E Taube, James W Jacobson, Tracy G Lively.
Am J Pharmacogenomics, 2005 Dec 13; 5(6). PMID: 16336001
Review.
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Lecia V Sequist, Daphne W Bell, Thomas J Lynch, Daniel A Haber.
J Clin Oncol, 2007 Feb 10; 25(5). PMID: 17290067
Highly Cited. Review.
Clinical trial designs for predictive marker validation in cancer treatment trials.
Daniel J Sargent, Barbara A Conley, Carmen Allegra, Laurence Collette.
J Clin Oncol, 2005 Mar 19; 23(9). PMID: 15774793
Highly Cited. Review.
Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
Marc Buyse, Sherene Loi, +18 authors, TRANSBIG Consortium.
J Natl Cancer Inst, 2006 Sep 07; 98(17). PMID: 16954471
Highly Cited.
Randomized phase III clinical trial designs for targeted agents.
Antje Hoering, Mike Leblanc, John J Crowley.
Clin Cancer Res, 2008 Jul 17; 14(14). PMID: 18628448    Free PMC article.
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
Edward H Romond, Edith A Perez, +22 authors, Norman Wolmark.
N Engl J Med, 2005 Oct 21; 353(16). PMID: 16236738
Highly Cited.
P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
H Elsaleh, B Powell, +4 authors, B Iacopetta.
Clin Cancer Res, 2001 May 15; 7(5). PMID: 11350904
Clinical trial methods to discover and validate predictive markers for treatment response in cancer.
Soonmyung Paik.
Biotechnol Annu Rev, 2003 Dec 04; 9. PMID: 14650930
Review.
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.
Fred R Hirsch, Marileila Varella-Garcia, +6 authors, Wilbur A Franklin.
J Clin Oncol, 2003 Sep 04; 21(20). PMID: 12953099
Highly Cited.
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Nasser Hanna, Frances A Shepherd, +17 authors, Paul A Bunn.
J Clin Oncol, 2004 May 01; 22(9). PMID: 15117980
Highly Cited.
Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset.
Sue-Jane Wang, Robert T O'Neill, H M James Hung.
Pharm Stat, 2007 Aug 11; 6(3). PMID: 17688238
Development of the 21-gene assay and its application in clinical practice and clinical trials.
Joseph A Sparano, Soonmyung Paik.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258979
Highly Cited. Review.
Individualization of therapy using Mammaprint: from development to the MINDACT Trial.
Stella Mook, Laura J Van't Veer, +2 authors, Fatima Cardoso.
Cancer Genomics Proteomics, 2007 Sep 20; 4(3). PMID: 17878518
Review.
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine.
Xian Zhou, Suyu Liu, +2 authors, J Jack Lee.
Clin Trials, 2008 Jun 19; 5(3). PMID: 18559407    Free PMC article.
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Christos S Karapetis, Shirin Khambata-Ford, +13 authors, John R Zalcberg.
N Engl J Med, 2008 Oct 24; 359(17). PMID: 18946061
Highly Cited.
Clinical trial designs for predictive biomarker validation: one size does not fit all.
Sumithra J Mandrekar, Daniel J Sargent.
J Biopharm Stat, 2009 Apr 23; 19(3). PMID: 19384694    Free PMC article.
Cetuximab for the treatment of colorectal cancer.
Derek J Jonker, Chris J O'Callaghan, +12 authors, Malcolm J Moore.
N Engl J Med, 2007 Nov 16; 357(20). PMID: 18003960
Highly Cited.
Prognostic and predictive markers in cancer.
Barbara A Conley, Sheila E Taube.
Dis Markers, 2004 Aug 24; 20(2). PMID: 15322312    Free PMC article.
Review.
On the efficiency of targeted clinical trials.
A Maitournam, R Simon.
Stat Med, 2004 Nov 20; 24(3). PMID: 15551403
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
David A Eberhard, Bruce E Johnson, +16 authors, Kenneth J Hillan.
J Clin Oncol, 2005 Jul 27; 23(25). PMID: 16043828
Highly Cited.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
Soonmyung Paik, Steven Shak, +12 authors, Norman Wolmark.
N Engl J Med, 2004 Dec 14; 351(27). PMID: 15591335
Highly Cited.
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.
Edith A Perez, Vera J Suman, +7 authors, Robert B Jenkins.
J Clin Oncol, 2006 Jul 01; 24(19). PMID: 16809727
Highly Cited.
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapies.
Fred R Hirsch, Giorgio V Scagliotti, +2 authors, Wilbur A Franklin.
Lung Cancer, 2003 Jul 18; 41 Suppl 1. PMID: 12867060
Review.
Erlotinib in previously treated non-small-cell lung cancer.
Frances A Shepherd, José Rodrigues Pereira, +17 authors, National Cancer Institute of Canada Clinical Trials Group.
N Engl J Med, 2005 Jul 15; 353(2). PMID: 16014882
Highly Cited.
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Federico Cappuzzo, Claudia Ligorio, +11 authors, Marileila Varella-Garcia.
J Thorac Oncol, 2007 May 03; 2(5). PMID: 17473658
Herceptin: increasing survival in metastatic breast cancer.
D Slamon.
Eur J Oncol Nurs, 2003 Jul 10; 4(Sa). PMID: 12849614
Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Philip D Bonomi, Lela Buckingham, John Coon.
Clin Cancer Res, 2007 Aug 03; 13(15 Pt 2). PMID: 17671150
Review.
Multiple testing in clinical trials.
P Bauer.
Stat Med, 1991 Jun 01; 10(6). PMID: 1831562
A gene-expression signature as a predictor of survival in breast cancer.
Marc J van de Vijver, Yudong D He, +18 authors, René Bernards.
N Engl J Med, 2002 Dec 20; 347(25). PMID: 12490681
Highly Cited.
Clinical application of the 70-gene profile: the MINDACT trial.
Fatima Cardoso, Laura Van't Veer, +3 authors, Martine J Piccart-Gebhart.
J Clin Oncol, 2008 Feb 09; 26(5). PMID: 18258980
Highly Cited.
Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
Wenyu Jiang, Boris Freidlin, Richard Simon.
J Natl Cancer Inst, 2007 Jun 29; 99(13). PMID: 17596577
Evaluating the efficiency of targeted designs for randomized clinical trials.
Richard Simon, Aboubakar Maitournam.
Clin Cancer Res, 2004 Oct 27; 10(20). PMID: 15501951
Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.
Jan Bogaerts, Fatima Cardoso, +12 authors, TRANSBIG consortium.
Nat Clin Pract Oncol, 2006 Oct 05; 3(10). PMID: 17019432
Review.
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.
Lucio Crinò, Federico Cappuzzo, +11 authors, Michael Cullen.
J Clin Oncol, 2008 Sep 10; 26(26). PMID: 18779612
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
Rafael G Amado, Michael Wolf, +9 authors, David D Chang.
J Clin Oncol, 2008 Mar 05; 26(10). PMID: 18316791
Highly Cited.
Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer.
H Elsaleh, D Joseph, +3 authors, B Iacopetta.
Lancet, 2000 Jun 01; 355(9217). PMID: 10832824
Highly Cited.
Clinical trial designs for prospective validation of biomarkers.
Sumithra J Mandrekar, Axel Grothey, Matthew P Goetz, Daniel J Sargent.
Am J Pharmacogenomics, 2005 Oct 04; 5(5). PMID: 16196501
Genomic advances and their impact on clinical trial design.
Sumithra J Mandrekar, Daniel J Sargent.
Genome Med, 2009 Jul 30; 1(7). PMID: 19638184    Free PMC article.
Randomized clinical trials with biomarkers: design issues.
Boris Freidlin, Lisa M McShane, Edward L Korn.
J Natl Cancer Inst, 2010 Jan 16; 102(3). PMID: 20075367    Free PMC article.
Highly Cited.
Current challenges for the early clinical development of anticancer drugs in the era of molecularly targeted agents.
Christophe Le Tourneau, Véronique Diéras, +2 authors, Xavier Paoletti.
Target Oncol, 2010 Apr 03; 5(1). PMID: 20361265
Review.
Biomarkers and surrogate end points--the challenge of statistical validation.
Marc Buyse, Daniel J Sargent, +2 authors, Aimery de Gramont.
Nat Rev Clin Oncol, 2010 Apr 07; 7(6). PMID: 20368727
Review.
Predictive biomarker validation in practice: lessons from real trials.
Sumithra J Mandrekar, Daniel J Sargent.
Clin Trials, 2010 Apr 16; 7(5). PMID: 20392785    Free PMC article.
Ethics of mandatory research biopsy for correlative end points within clinical trials in oncology.
Jeffrey Peppercorn, Iuliana Shapira, +8 authors, Monica M Bertagnolli.
J Clin Oncol, 2010 Apr 22; 28(15). PMID: 20406927    Free PMC article.
Personalized medicine in oncology: the future is now.
Richard L Schilsky.
Nat Rev Drug Discov, 2010 May 01; 9(5). PMID: 20431568
Review.
Biomarkers in colorectal cancer: the future is getting closer.
D Roda, A Cervantes.
Clin Transl Oncol, 2010 May 14; 12(4). PMID: 20462831
Envisioning the future of early anticancer drug development.
Timothy A Yap, Shahneen K Sandhu, Paul Workman, Johann S de Bono.
Nat Rev Cancer, 2010 Jun 11; 10(7). PMID: 20535131
Review.
Statistical consideration for clinical biomarker research in bladder cancer.
Shahrokh F Shariat, Yair Lotan, +4 authors, Nuria Malats.
Urol Oncol, 2010 Jul 09; 28(4). PMID: 20610277    Free PMC article.
Review.
Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer.
James F Rusling, Challa V Kumar, J Silvio Gutkind, Vyomesh Patel.
Analyst, 2010 Jul 09; 135(10). PMID: 20614087    Free PMC article.
Highly Cited. Review.
Translating cancer research into targeted therapeutics.
J S de Bono, Alan Ashworth.
Nature, 2010 Oct 01; 467(7315). PMID: 20882008
Highly Cited.
Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study.
L Licitra, R Mesia, +11 authors, J B Vermorken.
Ann Oncol, 2010 Nov 05; 22(5). PMID: 21048039    Free PMC article.
Highly Cited.
An accelerated pathway for targeted cancer therapies.
Mark McClellan, Joshua Benner, +6 authors, David Kessler.
Nat Rev Drug Discov, 2011 Feb 02; 10(2). PMID: 21283090
Implementing prognostic and predictive biomarkers in CRC clinical trials.
Sandra Van Schaeybroeck, Wendy L Allen, Richard C Turkington, Patrick G Johnston.
Nat Rev Clin Oncol, 2011 Feb 16; 8(4). PMID: 21321566
Review.
Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.
E Bria, M Milella, +8 authors, D Giannarelli.
Ann Oncol, 2011 Feb 18; 22(10). PMID: 21325444    Free PMC article.
Review.
Personalized colon cancer care in 2010.
Daniel V T Catenacci, Mark Kozloff, Hedy L Kindler, Blase Polite.
Semin Oncol, 2011 Mar 23; 38(2). PMID: 21421118    Free PMC article.
Review.
Genomic markers to tailor treatments: waiting or initiating?
Parvin Tajik, Patrick M Bossuyt.
Hum Genet, 2011 Apr 14; 130(1). PMID: 21487770    Free PMC article.
All-comers versus enrichment design strategy in phase II trials.
Sumithra J Mandrekar, Daniel J Sargent.
J Thorac Oncol, 2011 May 03; 6(4). PMID: 21532916    Free PMC article.
Somatic variation and cancer: therapies lost in the mix.
Andrew V Biankin, Thomas J Hudson.
Hum Genet, 2011 Jun 07; 130(1). PMID: 21643984
Review.
Translating biomarkers to clinical practice.
R H Perlis.
Mol Psychiatry, 2011 Jun 29; 16(11). PMID: 21709685    Free PMC article.
Review.
Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method.
Elena García-García, Carlos Gómez-Martín, +7 authors, Fernando López-Ríos.
Histopathology, 2011 Jul 21; 59(1). PMID: 21771023    Free PMC article.
The ethical use of mandatory research biopsies.
Erin M Olson, Nancy U Lin, Ian E Krop, Eric P Winer.
Nat Rev Clin Oncol, 2011 Aug 03; 8(10). PMID: 21808265    Free PMC article.
Review.
Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience.
Hazem El-Osta, David Hong, +7 authors, Razelle Kurzrock.
Oncologist, 2011 Aug 24; 16(9). PMID: 21859821    Free PMC article.
Quantifying factors for the success of stratified medicine.
Mark R Trusheim, Breon Burgess, +12 authors, Michael C Palmer.
Nat Rev Drug Discov, 2011 Nov 01; 10(11). PMID: 22037040
Review.
Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics.
Howard I Scher, Shelley Fuld Nasso, Eric H Rubin, Richard Simon.
Clin Cancer Res, 2011 Nov 03; 17(21). PMID: 22046024    Free PMC article.
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.
Rodrigo Dienstmann, Irene Braña, Jordi Rodon, Josep Tabernero.
Oncologist, 2011 Dec 03; 16(12). PMID: 22135123    Free PMC article.
Review.
Design of clinical trials for biomarker research in oncology.
Sumithra J Mandrekar, Daniel J Sargent.
Clin Investig (Lond), 2012 Mar 06; 1(12). PMID: 22389760    Free PMC article.
Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819.
Mary W Redman, John J Crowley, +2 authors, David R Gandara.
Clin Cancer Res, 2012 May 18; 18(15). PMID: 22592956    Free PMC article.
Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity.
David R Gandara, Tianhong Li, +6 authors, Mary W Redman.
Clin Lung Cancer, 2012 Jun 09; 13(5). PMID: 22677432    Free PMC article.
Personalized medicine using DNA biomarkers: a review.
Andreas Ziegler, Armin Koch, Katja Krockenberger, Anika Grosshennig.
Hum Genet, 2012 Jul 04; 131(10). PMID: 22752797    Free PMC article.
Review.
Study designs and statistical analyses for biomarker research.
Masahiko Gosho, Kengo Nagashima, Yasunori Sato.
Sensors (Basel), 2012 Sep 27; 12(7). PMID: 23012528    Free PMC article.
Review.
Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat.
Ont Health Technol Assess Ser, 2010 Jan 01; 10(23). PMID: 23074401    Free PMC article.
New treatments compared to established treatments in randomized trials.
Benjamin Djulbegovic, Ambuj Kumar, +10 authors, Iain Chalmers.
Cochrane Database Syst Rev, 2012 Oct 19; 10. PMID: 23076962    Free PMC article.
Incorporation of prognostic and predictive factors into glioma clinical trials.
Derek R Johnson, Evanthia Galanis.
Curr Oncol Rep, 2012 Nov 06; 15(1). PMID: 23125011    Free PMC article.
Review.
Moving from correlative science to predictive oncology.
Richard Simon.
EPMA J, 2010 Sep 01; 1(3). PMID: 23199082    Free PMC article.
Assessment of reproducibility of cancer survival risk predictions across medical centers.
Hung-Chia Chen, James J Chen.
BMC Med Res Methodol, 2013 Feb 22; 13. PMID: 23425000    Free PMC article.
Adaptive enrichment designs for clinical trials.
Noah Simon, Richard Simon.
Biostatistics, 2013 Mar 26; 14(4). PMID: 23525452    Free PMC article.
Phase III clinical trials that integrate treatment and biomarker evaluation.
Boris Freidlin, Zhuoxin Sun, Robert Gray, Edward L Korn.
J Clin Oncol, 2013 Apr 10; 31(25). PMID: 23569306    Free PMC article.
A review of phase II trial designs for initial marker validation.
Sumithra J Mandrekar, Ming-Wen An, Daniel J Sargent.
Contemp Clin Trials, 2013 May 15; 36(2). PMID: 23665336    Free PMC article.
Review.
Genomic biomarkers for personalized medicine: development and validation in clinical studies.
Shigeyuki Matsui.
Comput Math Methods Med, 2013 May 22; 2013. PMID: 23690882    Free PMC article.
Review.
Clinical significance of VEGFR-2 and ¹⁸F-FDG PET/CT SUVmax pretreatment score in predicting the long-term outcome of patients with locally advanced rectal cancer treated with neoadjuvant therapy.
Claudio V Sole, Felipe A Calvo, +6 authors, Jose L Carreras.
Eur J Nucl Med Mol Imaging, 2013 Jun 27; 40(11). PMID: 23801169
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
Fotios Loupakis, Chiara Cremolini, +17 authors, Heinz-Josef Lenz.
PLoS One, 2013 Jul 19; 8(7). PMID: 23861747    Free PMC article.
The interaction between prognostic and pharmacodynamic biomarkers.
L Bouranis, M Sperrin, +2 authors, A G Renehan.
Br J Cancer, 2013 Sep 05; 109(7). PMID: 24002599    Free PMC article.
Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups.
Michael J Sorich, Michael Coory, Brita A K Pekarsky.
PLoS One, 2013 Sep 10; 8(8). PMID: 24015225    Free PMC article.
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
Bradley J Atkinson, Diana H Cauley, +5 authors, Nizar M Tannir.
BJU Int, 2013 Sep 24; 113(3). PMID: 24053120    Free PMC article.
Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs.
Brenda F Kurland, Robert K Doot, +2 authors, Paul E Kinahan.
Clin Trials, 2013 Oct 31; 10(6). PMID: 24169628    Free PMC article.
Treatment of pancreatic cancer: what can we really predict today?
Jean-Baptiste Bachet, Raphael Marechal, Jean-Luc Van Laethem.
Cancers (Basel), 2011 Jan 01; 3(1). PMID: 24212636    Free PMC article.
Predictive and prognostic factors in colorectal cancer: a personalized approach.
Myutan Kulendran, John F Stebbing, Christopher G Marks, Timothy A Rockall.
Cancers (Basel), 2011 Jan 01; 3(2). PMID: 24212777    Free PMC article.
Evaluating many treatments and biomarkers in oncology: a new design.
Richard Kaplan, Timothy Maughan, +4 authors, Mahesh Parmar.
J Clin Oncol, 2013 Nov 20; 31(36). PMID: 24248692    Free PMC article.
Biomarker enrichment strategies: matching trial design to biomarker credentials.
Boris Freidlin, Edward L Korn.
Nat Rev Clin Oncol, 2013 Nov 28; 11(2). PMID: 24281059
Review.
Drug-diagnostics co-development in oncology.
Richard Simon.
Front Oncol, 2014 Jan 07; 3. PMID: 24392354    Free PMC article.
Review.
Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development.
Jan Stenvang, Iben Kümler, +4 authors, José M A Moreira.
Front Oncol, 2014 Jan 09; 3. PMID: 24400218    Free PMC article.
Review.
A Bayesian Dose-finding Design for Oncology Clinical Trials of Combinational Biological Agents.
Chunyan Cai, Ying Yuan, Yuan Ji.
J R Stat Soc Ser C Appl Stat, 2014 Feb 11; 63(1). PMID: 24511160    Free PMC article.
Randomized reverse marker strategy design for prospective biomarker validation.
Kevin H Eng.
Stat Med, 2014 Mar 19; 33(18). PMID: 24639051    Free PMC article.
Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.
J Wason, A Marshall, +2 authors, N Stallard.
Br J Cancer, 2014 Mar 29; 110(8). PMID: 24667651    Free PMC article.
Adjusting for misclassification in a stratified biomarker clinical trial.
Chunling Liu, Aiyi Liu, +2 authors, Susan Halabi.
Stat Med, 2014 Apr 16; 33(18). PMID: 24733510    Free PMC article.
Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment.
Ming-Wen An, Sumithra J Mandrekar, Martin J Edelman, Daniel J Sargent.
Contemp Clin Trials, 2014 Apr 29; 38(2). PMID: 24768938    Free PMC article.
Increasing efficiency for estimating treatment-biomarker interactions with historical data.
Philip S Boonstra, Jeremy Mg Taylor, Bhramar Mukherjee.
Stat Methods Med Res, 2014 May 24; 25(6). PMID: 24855118    Free PMC article.
Stratification and partial ascertainment of biomarker value in biomarker-driven clinical trials.
Richard Simon.
J Biopharm Stat, 2014 Jun 18; 24(5). PMID: 24935478    Free PMC article.
Toward rapid, high-sensitivity, volume-constrained biomarker quantification and validation using backscattering interferometry.
Ian R Olmsted, Mohamed Hassanein, +4 authors, Darryl J Bornhop.
Anal Chem, 2014 Jun 24; 86(15). PMID: 24954171    Free PMC article.
Choosing inclusion criteria that minimize the time and cost of clinical trials.
Charles F Babbs.
World J Methodol, 2014 Oct 22; 4(2). PMID: 25332910    Free PMC article.
Prognostic Impact of Deficient DNA Mismatch Repair and Mutations in KRAS, and BRAF in Patients with Lymph Node-Positive Colon Cancer.
Aziz Zaanan, Jean-Baptiste Bachet, Thierry André, Frank A Sinicrope.
Curr Colorectal Cancer Rep, 2014 Nov 12; 10(3). PMID: 25386108    Free PMC article.
Adaptive designs for subpopulation analysis optimizing utility functions.
Alexandra C Graf, Martin Posch, Franz Koenig.
Biom J, 2014 Nov 18; 57(1). PMID: 25399844    Free PMC article.
Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine.
Sumithra J Mandrekar, Daniel J Sargent.
Chin Clin Oncol, 2014 Nov 22; 3(2). PMID: 25414851    Free PMC article.
Methods and challenges in quantitative imaging biomarker development.
Richard G Abramson, Kirsteen R Burton, +8 authors, Rathan M Subramaniam.
Acad Radiol, 2014 Dec 08; 22(1). PMID: 25481515    Free PMC article.
Review.
Guidance for pharmacogenomic biomarker testing in labels of FDA-approved drugs.
Alexandre Vivot, Isabelle Boutron, Philippe Ravaud, Raphaël Porcher.
Genet Med, 2014 Dec 19; 17(9). PMID: 25521333
Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.
Shakun M Malik, Richard Pazdur, +7 authors, Fred R Hirsch.
J Thorac Oncol, 2014 Dec 19; 9(10). PMID: 25521397    Free PMC article.
Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Nozomu Fuse, Yasutoshi Kuboki, +14 authors, Atsushi Ohtsu.
Gastric Cancer, 2015 Feb 16; 19(1). PMID: 25682441
Adaptive clinical trial designs in oncology.
Yong Zang, J Jack Lee.
Chin Clin Oncol, 2015 Mar 27; 3(4). PMID: 25811018    Free PMC article.
Genotype-based clinical trials in cardiovascular disease.
Naveen L Pereira, Daniel J Sargent, Michael E Farkouh, Charanjit S Rihal.
Nat Rev Cardiol, 2015 May 06; 12(8). PMID: 25940926    Free PMC article.
Review.
Designing a study to evaluate the benefit of a biomarker for selecting patient treatment.
Holly Janes, Marshall D Brown, Margaret S Pepe.
Stat Med, 2015 Jun 27; 34(27). PMID: 26112650    Free PMC article.
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer.
Jeanne Mendell, Daniel J Freeman, +11 authors, Robert A Beckman.
EBioMedicine, 2015 Jul 03; 2(3). PMID: 26137564    Free PMC article.
Actionable pharmacogenetic markers for prediction and prognosis in breast cancer.
Keith Sacco, Godfrey Grech.
EPMA J, 2015 Jul 24; 6(1). PMID: 26203310    Free PMC article.
Clinical Neuropathology practice guide 5-2015: MGMT methylation pyrosequencing in glioblastoma: unresolved issues and open questions.
Michal Bienkowski, Anna S Berghoff, +4 authors, Matthias Preusser.
Clin Neuropathol, 2015 Aug 22; 34(5). PMID: 26295302    Free PMC article.
Review.
Molecular and clinical implementations of ovarian cancer mouse avatar models.
Amira A Zayed, Sumithra J Mandrekar, Paul Haluska.
Chin Clin Oncol, 2015 Sep 27; 4(3). PMID: 26408297    Free PMC article.
Review.
Patient-centric trials for therapeutic development in precision oncology.
Andrew V Biankin, Steven Piantadosi, Simon J Hollingsworth.
Nature, 2015 Oct 16; 526(7573). PMID: 26469047
Highly Cited. Review.
Lung cancer biomarkers, targeted therapies and clinical assays.
Jai N Patel, Jennifer L Ersek, Edward S Kim.
Transl Lung Cancer Res, 2015 Dec 03; 4(5). PMID: 26629419    Free PMC article.
Review.
Clinical trial designs incorporating predictive biomarkers.
Lindsay A Renfro, Himel Mallick, +2 authors, Sumithra J Mandrekar.
Cancer Treat Rev, 2016 Feb 02; 43. PMID: 26827695    Free PMC article.
Review.
Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Miranta Antoniou, Andrea L Jorgensen, Ruwanthi Kolamunnage-Dona.
PLoS One, 2016 Feb 26; 11(2). PMID: 26910238    Free PMC article.
Review.
Optimal marker-strategy clinical trial design to detect predictive markers for targeted therapy.
Yong Zang, Suyu Liu, Ying Yuan.
Biostatistics, 2016 Mar 10; 17(3). PMID: 26951724    Free PMC article.
Precision oncology: A new era of cancer clinical trials.
Lindsay A Renfro, Ming-Wen An, Sumithra J Mandrekar.
Cancer Lett, 2016 Mar 19; 387. PMID: 26987624    Free PMC article.
Review.
Bayesian Two-stage Biomarker-based Adaptive Design for Targeted Therapy Development.
Xuemin Gu, Nan Chen, +4 authors, J Jack Lee.
Stat Biosci, 2016 Sep 13; 8(1). PMID: 27617040    Free PMC article.
Optimal sequential enrichment designs for phase II clinical trials.
Yong Zang, Ying Yuan.
Stat Med, 2016 Sep 20; 36(1). PMID: 27640874    Free PMC article.
Strategies for power calculations in predictive biomarker studies in survival data.
Dung-Tsa Chen, Po-Yu Huang, +4 authors, Jhanelle E Gray.
Oncotarget, 2016 Sep 24; 7(49). PMID: 27661007    Free PMC article.
Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Paolo A Ascierto, Sanjiv Agarwala, +33 authors, Magdalena Thurin.
J Transl Med, 2016 Nov 17; 14(1). PMID: 27846884    Free PMC article.
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II - clinical validation and regulatory considerations.
Kevin K Dobbin, Alessandra Cesano, +10 authors, Magdalena Thurin.
J Immunother Cancer, 2016 Nov 29; 4. PMID: 27891226    Free PMC article.
Review.
Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review.
Miranta Antoniou, Ruwanthi Kolamunnage-Dona, Andrea L Jorgensen.
J Pers Med, 2017 Jan 27; 7(1). PMID: 28125057    Free PMC article.
Review.
Precision medicine needs randomized clinical trials.
Everardo D Saad, Xavier Paoletti, Tomasz Burzykowski, Marc Buyse.
Nat Rev Clin Oncol, 2017 Feb 09; 14(5). PMID: 28169302
Review.
Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations.
Savita Nandal, Tal Burt.
Int J Mol Sci, 2017 Feb 22; 18(2). PMID: 28218733    Free PMC article.
Review.
Phase II cancer clinical trials for biomarker-guided treatments.
Sin-Ho Jung.
J Biopharm Stat, 2017 Sep 14; 28(2). PMID: 28902567    Free PMC article.
On Enrichment Strategies for Biomarker Stratified Clinical Trials.
Xiaofei Wang, Jingzhu Zhou, Ting Wang, Stephen L George.
J Biopharm Stat, 2017 Sep 22; 28(2). PMID: 28933670    Free PMC article.
Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers.
Weichung Joe Shih, Yong Lin.
Stat Med, 2017 Dec 06; 37(5). PMID: 29205435    Free PMC article.
Considerations for biomarker-targeted intervention strategies for tuberculosis disease prevention.
Andrew Fiore-Gartland, Lindsay N Carpp, +8 authors, Mark Hatherill.
Tuberculosis (Edinb), 2018 Mar 22; 109. PMID: 29559122    Free PMC article.
Roadmap for optimizing the clinical utility of emotional stress paradigms in human neuroimaging research.
Timothy J McDermott, Namik Kirlic, Robin L Aupperle.
Neurobiol Stress, 2018 Jun 12; 8. PMID: 29888309    Free PMC article.
Review.
Auxiliary variable-enriched biomarker-stratified design.
Ting Wang, Xiaofei Wang, +2 authors, Stephen L George.
Stat Med, 2018 Sep 18; 37(30). PMID: 30221368    Free PMC article.
Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).
Xabier García-Albéniz, Vicente Alonso, +17 authors, Joan Maurel.
Oncologist, 2019 Jun 27; 24(11). PMID: 31235483    Free PMC article.
A comparison of subgroup identification methods in clinical drug development: Simulation study and regulatory considerations.
Cynthia Huber, Norbert Benda, Tim Friede.
Pharm Stat, 2019 Jul 05; 18(5). PMID: 31270933    Free PMC article.
Paclitaxel Response Can Be Predicted With Interpretable Multi-Variate Classifiers Exploiting DNA-Methylation and miRNA Data.
Alexandra Bomane, Anthony Gonçalves, Pedro J Ballester.
Front Genet, 2019 Nov 12; 10. PMID: 31708973    Free PMC article.
Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.
Charlotte I Stroes, Sandor Schokker, +22 authors, Hanneke W M van Laarhoven.
J Clin Oncol, 2019 Dec 07; 38(5). PMID: 31809243    Free PMC article.
Evaluation of heart failure biomarker tests: a survey of statistical considerations.
Arkendra De, Kristen Meier, +4 authors, Gene Pennello.
J Cardiovasc Transl Res, 2013 May 15; 6(4). PMID: 23670231
Review.
Considerations for the successful co-development of targeted cancer therapies and companion diagnostics.
Jane Fridlyand, Richard M Simon, +7 authors, Howard I Scher.
Nat Rev Drug Discov, 2013 Sep 07; 12(10). PMID: 24008432
Review.
An alternative method to analyse the biomarker-strategy design.
Cornelia Ursula Kunz, Thomas Jaki, Nigel Stallard.
Stat Med, 2018 Sep 28; 37(30). PMID: 30260533    Free PMC article.
Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape.
Patrick P J Phillips, Carole D Mitnick, +3 authors, Andrew J Nunn.
PLoS Med, 2019 Mar 23; 16(3). PMID: 30901331    Free PMC article.
Review.
Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma.
Shuang G Zhao, Menggang Yu, +9 authors, Daniel R Wahl.
Neuro Oncol, 2019 May 24; 21(9). PMID: 31121035    Free PMC article.
Designing precision medicine trials to yield a greater population impact.
Ying-Qi Zhao, Michael L LeBlanc.
Biometrics, 2019 Oct 11; 76(2). PMID: 31598964    Free PMC article.
Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer.
James Meehan, Mark Gray, +8 authors, Arran K Turnbull.
Front Oncol, 2020 May 12; 10. PMID: 32391281    Free PMC article.
Review.
Principles of Good Clinical Trial Design.
Ming-Wen An, Quyen Duong, Jennifer Le-Rademacher, Sumithra J Mandrekar.
J Thorac Oncol, 2020 May 18; 15(8). PMID: 32417343    Free PMC article.
Biomarkers for Aging Identified in Cross-sectional Studies Tend to Be Non-causative.
Paul G Nelson, Daniel E L Promislow, Joanna Masel.
J Gerontol A Biol Sci Med Sci, 2019 Jul 30; 75(3). PMID: 31353411    Free PMC article.
Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations.
Chen Hu, James J Dignam.
JCO Precis Oncol, 2020 Sep 15; 3. PMID: 32923854    Free PMC article.
Review.
Comparison of Clopidogrel and Ticlopidine/Ginkgo Biloba in Patients With Clopidogrel Resistance and Carotid Stenting.
Jong-Won Chung, Suk Jae Kim, +8 authors, Oh Young Bang.
Front Neurol, 2019 Feb 15; 10. PMID: 30761076    Free PMC article.
Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.
Vincenzo Di Marzo, Diego Centonze.
CNS Neurosci Ther, 2014 Dec 06; 21(3). PMID: 25475413    Free PMC article.
Review.
Is It Possible to Personalize the Diagnosis and Treatment of Breast Cancer during Pregnancy?
Petra Tesarova, David Pavlista, Antonin Parizek.
J Pers Med, 2021 Jan 01; 11(1). PMID: 33379383    Free PMC article.
Review.
Statistical Considerations for Subgroup Analyses.
Xiaofei Wang, Steven Piantadosi, Jennifer Le-Rademacher, Sumithra J Mandrekar.
J Thorac Oncol, 2020 Dec 30; 16(3). PMID: 33373692    Free PMC article.
The Epithelial-Mesenchymal Transcription Factor Slug Predicts Survival Benefit of Up-Front Surgery in Head and Neck Cancer.
Herbert Riechelmann, Teresa Bernadette Steinbichler, +5 authors, Jozsef Dudas.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33673269    Free PMC article.
Design and analysis of biomarker-integrated clinical trials with adaptive threshold detection and flexible patient enrichment.
Ting Wang, Xiaofei Wang, Stephen L George, Haibo Zhou.
J Biopharm Stat, 2020 Nov 12; 30(6). PMID: 33175640    Free PMC article.